Drug Profile
Research programme: pain therapeutics - Galleon Pharmaceuticals
Alternative Names: GAL-044; GAL-044 IV; GAL-044 oral (PO)Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Galleon Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Pain
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Postoperative-pain in USA (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Postoperative-pain in USA (PO)
- 13 Oct 2014 Preclinical development is ongoing in USA